Stress Wakes a Quiet Arthritic Joint Through Brown Fat

A 50-milliliter tube is not much of a prison, but for a mouse it is enough: four hours a day, three days running, and an ankle that had been calm for weeks swells up again. How does a worry in the head reach a joint? In mice with arthritis in remission, the route ran from the sympathetic nervous system to a pad of brown fat that released interleukin-6 into the blood, and fibroblasts lining the joint answered by calling in neutrophils. That chain comes from a team at Chiba University in Japan, and most links in it were tested by taking them away.

Psychological stress has been tied to worse rheumatoid arthritis for decades, and a body that has been hurt once seems to keep the memory (in mice, stress early in life can prime brain cells so that stress in adulthood lands harder). Yet nobody had a clean account of how a mood could reignite a joint the disease had already left, which is exactly the situation the new mouse model was built to mimic.

A Restraint Tube and a Quiet Ankle

The team, led by Shigeru Tanaka and Hiroshi Nakajima, first gave young adult mice (both sexes, 8 to 12 weeks old) an arthritis by injecting an antigen into one joint, then waited at least three weeks for it to settle into remission. Then came the tube. In the core experiment, between 9 and 12 mice per condition were confined, and their ankles thickened while tissue slides showed fresh inflammation in the joint lining. Mice put under anesthesia during restraint did not flare, which suggests that being awake to the experience mattered.

The obvious suspects were not required. Strip out T cells or B cells, the lymphocytes that normally run autoimmune disease, and the stressed mice still flared, though the swelling was less pronounced without T cells.

Interleukin-6, a signaling protein best known for stoking inflammation, was the next candidate, and the evidence built from several directions. An antibody against its receptor blunted the stress flare; surgically removing brown fat, or chemically wiping out the sympathetic nerves, dampened it too; and injecting a tiny dose of interleukin-6 itself (2 ng a day for three days) produced swelling close to what the tube had. The authors judge it both necessary and sufficient for the flare in this model, which is a claim about one mouse arthritis and nothing broader.

The team reads this as a sign that the immune system’s usual cast is not the whole story. As Tanaka, an assistant professor at Chiba, puts it, “stress can activate processes within other tissues that contribute to the return of joint inflammation.” In this case the other tissue is brown fat, a type of body fat that makes heat, and after restraint it produced more interleukin-6 (as earlier mouse work on stress also found) and plasma levels rose; the flare also returned, milder, when stress came after eight weeks of rest.

Who in the joint was listening? Single-cell sequencing of the synovium, the membrane lining the joint, pointed to a population of fibroblasts carrying gp130, a docking component for interleukin-6, and mice engineered to lack it in those fibroblasts showed no stress flare at all, even though the same animals had reacted more strongly to the original arthritis injection. Given interleukin-6 and its soluble receptor, cultured mouse fibroblasts made more of a chemokine (CXCL1), a chemical summons for neutrophils, the white blood cells that arrive first at an injury, and a drug blocking the neutrophil receptor for that summons cut the stress-triggered swelling.

Human cells behaved similarly in a dish: fibroblasts from nine patients’ joints made more CXCL1 under the same two proteins. Tissue cells have been implicated elsewhere in autoimmune flares, too; in a small human study ScholarPeer covered, outer-skin cells looked central to the chain of signals that sunlight set off in lupus skin. It’s a pattern worth watching.

A drug that blocks the beta-3 receptor, the doorway through which sympathetic signals switch on brown fat, lowered interleukin-6 in the blood, calmed the swelling and cut neutrophil numbers in the joint in groups of 10 to 11 mice. That is a result in mice, though, and the authors are plain that the drug’s dose, specificity and safety all need evaluating before anyone thinks of patients.

The press release goes further than the paper in two places. It says stress works independently of lymphocytes and offers a biological explanation of flares in people, yet the paper shows flares surviving T-cell and B-cell depletion with the authors allowing that those cells may amplify the inflammation, and its human data are a correlation, not a mechanism.

A Gene Variant and a Stress Questionnaire

The human evidence is thinner and, by the authors’ own description, observational. Nearly one in three of the patients (all East Asian) carried at least one copy of Trp64Arg, a gene variant that makes cells less responsive to stress hormones. Among patients without it, higher scores on a perceived-stress questionnaire went with higher disease activity, a weak but significant link; among carriers, the link was attenuated. This cannot show that stress changed anyone’s disease, and the patient numbers sit in the paper’s supplementary tables.

Prof. Hiroshi Nakajima, who co-led the work, says that “targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system.” Whether stress turns on interleukin-6 from brown fat in people at all remains to be determined, which is the question that decides whether this is a mouse story or a human one.

FAQ